Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This study is being done to answer the following question:
Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug
called zanidatamab to the usual combination of drugs?
We are doing this study because we want to find out if this approach is better or worse than
the usual approach for this type of cancer. The usual approach is defined as care most people
get for gastroesophageal cancer